Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis

被引:5
|
作者
Holz, Frank G. [1 ]
Tadayoni, Ramin [3 ]
Beatty, Stephen [4 ]
Berger, Alan R. [5 ,6 ]
Cereda, Matteo G. [7 ]
Hykin, Philip [8 ]
Hoyng, Carel B. [10 ]
Wittrup-Jensen, Kim [2 ]
Altemark, Andreas [2 ]
Nilsson, Jonas [11 ]
Kim, Kun [12 ]
Sivaprasad, Sobha [8 ,9 ]
机构
[1] Univ Bonn, Dept Ophthalmol, Bonn, Germany
[2] Bayer Pharmaceut, Berlin, Germany
[3] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, Paris, France
[4] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland
[5] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[6] St Michaels Hosp, Toronto, ON, Canada
[7] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy
[8] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England
[9] Kings Coll Hosp London, Dept Ophthalmol, London, England
[10] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands
[11] Real World Strategy & Analyt, Mapi Grp, Stockholm, Sweden
[12] AstraZeneca Nord Balt, Hlth Econ, Sodertalje, Sweden
关键词
AURA; Intravitreal ranibizumab; Neovascular age-related macular degeneration; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; LIFE; AMD;
D O I
10.1159/000449001
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA. Methods: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). The response variables analysed were mean change in visual acuity over 2 years (analysed via PCA) and no decline in visual acuity at 2 years compared with baseline (analysed via PLS-DA). Results: The AURA dataset comprised 2,227 patients and 132 variables. Using PCA and PLS-DA, we found that the number of ranibizumab injections, clinic and monitoring visits, number of optical coherence tomography scans and ophthalmoscopies correlated with a change in visual acuity at Years 1 and 2, and are therefore key drivers of treatment success. Conclusion: This is a novel approach to graphically explore relationships between multiple correlated covariates and outcomes in real-life ophthalmology studies. It identified a number of variables that are positively linked with treatment outcomes. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:49 / 55
页数:7
相关论文
共 50 条
  • [22] Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration
    Tadayoni, Ramin
    Sararols, Laura
    Weissgerber, Georges
    Verma, Rohini
    Clemens, Andreas
    Holz, Frank G.
    OPHTHALMOLOGICA, 2021, 244 (02) : 93 - 101
  • [23] Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment
    Oca, Ana I.
    Perez-Sala, Alvaro
    Pariente, Ana
    Ochoa, Rodrigo
    Velilla, Sara
    Pelaez, Rafael
    Larrayoz, Ignacio M.
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):
  • [24] Bacillary Detachment in Neovascular Age-Related Macular Degeneration Incidence, Clinical Features, and Response to Anti-VEGF Therapy
    Yordi, Sari
    Sarici, Kubra
    Cetin, Hasan
    Lunasco, Leina M.
    Le, Thuy K.
    Sevgi, Duriye Damla
    Zahid, Robert
    Meng, Xiangyi
    Reese, Jamie L.
    Srivastava, Sunil K.
    Ehlers, Justis P.
    OPHTHALMOLOGY RETINA, 2022, 6 (11): : 1061 - 1069
  • [25] Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in Neovascular Age-Related Macular Degeneration
    Holekamp, Nancy M.
    Liu, Ying
    Yeh, Wei-Shi
    Chia, Yifeng
    Kiss, Szilard
    Almony, Arghavan
    Kowalski, Jonathan W.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 157 (04) : 825 - 833
  • [27] Suspension of Anti-VEGF Treatment Does Not Affect Expansion of RPE Atrophy in Neovascular Age-Related Macular Degeneration
    Chujo, Shinichiro
    Matsubara, Hisashi
    Matsui, Yoshitsugu
    Sugimoto, Masahiko
    Kondo, Mineo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (11)
  • [28] Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
    Fu, Yingbin
    Zhang, Zhao
    Webster, Keith A.
    Paulus, Yannis M.
    BIOMOLECULES, 2024, 14 (03)
  • [29] PHARMACOGENOMICS OF RESPONSE TO ANTI-VEGF THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
    Dedania, Vaidehi S.
    Grob, Seanna
    Zhang, Kang
    Bakri, Sophie J.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (03): : 381 - 391
  • [30] Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
    Veluswamy, Balaji
    Lee, Andy
    Mirza, Rukhsana G.
    Gill, Manjot K.
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 1565 - 1572